• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.LRRK2 相关性帕金森病路易体病理的临床相关性。
JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.
2
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.LRRK2 基因突变相关帕金森病但无认知障碍患者的大脑皮层参与。
Acta Neuropathol. 2010 Aug;120(2):155-67. doi: 10.1007/s00401-010-0669-y. Epub 2010 Mar 16.
3
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.欧洲散发性帕金森病中LRRK2基因第41外显子突变
Arch Neurol. 2007 Mar;64(3):425-30. doi: 10.1001/archneur.64.3.425.
4
Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.富含亮氨酸重复激酶 2 与多巴胺能神经元中的内质网有关,并在帕金森病的路易体核心中积累。
J Neuropathol Exp Neurol. 2010 Sep;69(9):959-72. doi: 10.1097/NEN.0b013e3181efc01c.
5
Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.与LRRK2基因Ile1371Val突变相关的帕金森病神经病理学
Mov Disord. 2007 Jan 15;22(2):275-8. doi: 10.1002/mds.21281.
6
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.在帕金森综合征和额颞叶变性的病理系列中筛查LRRK2基因G2019S突变和1441密码子突变。
J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19.
7
Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.帕金森病伴 G2019S LRRK2 突变而无路易体病理。
Mov Disord Clin Pract. 2024 Jul;11(7):874-878. doi: 10.1002/mdc3.14068. Epub 2024 May 16.
8
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.导致无路易小体帕金森病的G2019S LRRK2突变。
J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. doi: 10.1136/jnnp.2006.107904. Epub 2007 Jan 8.
9
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.西班牙帕金森病患者的LRRK2突变:频率、临床特征及不完全外显率
Arch Neurol. 2006 Mar;63(3):377-82. doi: 10.1001/archneur.63.3.377.
10
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.撒丁岛帕金森病患者群体中五个LRRK2突变的基因分析:G2019S和R1441C突变在散发性帕金森病患者中的重要性
Parkinsonism Relat Disord. 2009 May;15(4):277-80. doi: 10.1016/j.parkreldis.2008.06.009. Epub 2008 Sep 20.

引用本文的文献

1
Stigmasterol Alleviates Levodopa-Induced Dyskinesia in 6-OHDA-Induced Parkinsonian Rats.豆甾醇减轻6-羟基多巴胺诱导的帕金森病大鼠的左旋多巴诱导的异动症。
Neurochem Res. 2025 Sep 18;50(5):304. doi: 10.1007/s11064-025-04555-z.
2
Longitudinal decline in striatal DAT binding in LRRK2 Parkinson's disease: connections with CSF α-synuclein seeding activity.LRRK2帕金森病中纹状体多巴胺转运体结合的纵向下降:与脑脊液α-突触核蛋白种子活性的关联
J Neurol. 2025 Sep 13;272(9):630. doi: 10.1007/s00415-025-13359-8.
3
Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort.PPMI队列中散发性和遗传性帕金森病的基线α-突触核蛋白播种活性与疾病进展
EBioMedicine. 2025 Aug 6;119:105866. doi: 10.1016/j.ebiom.2025.105866.
4
Templating of monomeric alpha-synuclein results in inflammation and SNpc dopamine neuron death in a genetic mouse model of induced synucleinopathy.在诱导性突触核蛋白病的基因小鼠模型中,单体α-突触核蛋白的模板化会导致炎症和黑质致密部多巴胺能神经元死亡。
Sci Rep. 2025 Jul 22;15(1):26537. doi: 10.1038/s41598-025-10705-8.
5
Accumulation of LRRK2-associated phospho-Rab12 degenerative lysosomes in tauopathies.富含亮氨酸重复激酶2相关磷酸化Rab12的退行性溶酶体在tau蛋白病中的积累。
bioRxiv. 2025 Jun 9:2025.06.06.658328. doi: 10.1101/2025.06.06.658328.
6
Recent advances in targeting LRRK2 for Parkinson's disease treatment.针对帕金森病治疗靶向亮氨酸丰富重复激酶2(LRRK2)的最新进展。
J Transl Med. 2025 Jul 8;23(1):754. doi: 10.1186/s12967-025-06354-0.
7
Dopamine and cortical neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction.多巴胺与携带不同帕金森氏症突变的皮层神经元在溶酶体和线粒体功能障碍方面存在差异。
NPJ Parkinsons Dis. 2025 Jun 20;11(1):177. doi: 10.1038/s41531-025-01048-2.
8
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.突触核蛋白病中的α-突触核蛋白病理学:机制、生物标志物及治疗挑战
Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405.
9
Neuropathological examination of 12 cases of familial Parkinson's disease with LRRK2 I2020T mutation including tau and TDP-43 pathology.对12例携带LRRK2 I2020T突变的家族性帕金森病患者进行神经病理学检查,包括tau蛋白和TDP - 43病理学检查。
J Neurol. 2025 Jun 9;272(7):450. doi: 10.1007/s00415-025-13148-3.
10
LRRK2-mediated mitochondrial dysfunction in Parkinson's disease.帕金森病中由LRRK2介导的线粒体功能障碍
Biochem J. 2025 May 28;482(11):BCJ20253062. doi: 10.1042/BCJ20253062.

本文引用的文献

1
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.是时候重新定义帕金森病了?帕金森病定义MDS特别工作组的介绍性声明
Mov Disord. 2014 Apr;29(4):454-62. doi: 10.1002/mds.25844. Epub 2014 Mar 11.
2
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.帕金森病痴呆:α-突触核蛋白、tau 和淀粉样β 病理学的汇聚。
Nat Rev Neurosci. 2013 Sep;14(9):626-36. doi: 10.1038/nrn3549. Epub 2013 Jul 31.
3
Parkin disease: a clinicopathologic entity?帕金森病:一种临床病理实体?
JAMA Neurol. 2013 May;70(5):571-9. doi: 10.1001/jamaneurol.2013.172.
4
α-Synuclein oligomers and clinical implications for Parkinson disease.α-突触核蛋白寡聚物与帕金森病的临床意义。
Ann Neurol. 2013 Feb;73(2):155-69. doi: 10.1002/ana.23746. Epub 2012 Dec 7.
5
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.病理性α-突触核蛋白的传递会在非转基因小鼠中引发类似帕金森病的神经退行性变。
Science. 2012 Nov 16;338(6109):949-53. doi: 10.1126/science.1227157.
6
Neuropathologic substrates of Parkinson disease dementia.帕金森病痴呆的神经病理学基础。
Ann Neurol. 2012 Oct;72(4):587-98. doi: 10.1002/ana.23659. Epub 2012 Oct 4.
7
The neuropathology of genetic Parkinson's disease.遗传帕金森病的神经病理学。
Mov Disord. 2012 Jun;27(7):831-42. doi: 10.1002/mds.24962. Epub 2012 Mar 26.
8
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.帕金森病遗传学的综合研究综述和系统荟萃分析:PDGene 数据库。
PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.
9
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.帕金森病和非帕金森病 LRRK2 G2019S 突变携带者的表型。
Neurology. 2011 Jul 26;77(4):325-33. doi: 10.1212/WNL.0b013e318227042d. Epub 2011 Jul 13.
10
α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.α-突触核蛋白抑制可逆转路易体痴呆小鼠模型的突触和记忆缺陷。
J Neurosci. 2011 Jul 6;31(27):10076-87. doi: 10.1523/JNEUROSCI.0618-11.2011.

LRRK2 相关性帕金森病路易体病理的临床相关性。

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

机构信息

The Edmond J. Safra Program in Parkinson's Disease, University Health Network, Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

出版信息

JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.

DOI:10.1001/jamaneurol.2014.2704
PMID:25401511
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4399368/
Abstract

IMPORTANCE

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 mutation carriers are generally indistinguishable from those of patients with sporadic PD. However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a neuropathological hallmark of PD. We investigated whether the presence or absence of LBs correlates with different clinical features in LRRK2-related PD.

OBSERVATIONS

We describe genetic, clinical, and neuropathological findings of 37 cases of LRRK2-related PD including 33 published and 4 unpublished cases through October 2013. Among the different mutations, the LRRK2 p.G2019S mutation was most frequently associated with LB pathology. Nonmotor features of cognitive impairment/dementia, anxiety, and orthostatic hypotension were correlated with the presence of LBs. In contrast, a primarily motor phenotype was associated with a lack of LBs.

CONCLUSIONS AND RELEVANCE

To our knowledge, this is the first report of clinicopathological correlations in a series of LRRK2-related PD cases. Findings from this selected group of patients with PD demonstrated that parkinsonian motor features can occur in the absence of LBs. However, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonian symptom complex including cognitive impairment.

摘要

重要性

富含亮氨酸重复激酶 2 (LRRK2) 突变是迄今为止已知的最常见的遗传帕金森病 (PD) 病因。表现出 LRRK2 突变携带者的临床特征通常与散发性 PD 患者的特征无法区分。然而,一些与 LRRK2 突变相关的 PD 病例缺乏路易体 (LB),这是 PD 的神经病理学标志。我们研究了 LB 的存在与否是否与 LRRK2 相关 PD 的不同临床特征相关。

观察结果

我们描述了 37 例 LRRK2 相关 PD 的遗传、临床和神经病理学发现,包括 2013 年 10 月之前的 33 例已发表和 4 例未发表的病例。在不同的突变中,LRRK2 p.G2019S 突变最常与 LB 病理相关。认知障碍/痴呆、焦虑和直立性低血压等非运动特征与 LB 的存在相关。相比之下,主要的运动表型与缺乏 LB 相关。

结论和相关性

据我们所知,这是一系列 LRRK2 相关 PD 病例临床病理相关性的首次报告。来自这组选定的 PD 患者的研究结果表明,帕金森运动特征可能在没有 LB 的情况下出现。然而,LRRK2 相关 PD 中的 LB 病理可能是更广泛的帕金森症状复合体的标志物,包括认知障碍。